Multus is a technology company.
Multus has raised $12.3M across 3 funding rounds.
Multus has raised $12.3M in total across 3 funding rounds.
Multus has raised $12.3M in total across 3 funding rounds.
Multus's investors include Astanor Ventures, Autism Impact Fund, Big Idea Ventures, LombardStreet Ventures, Mandi Ventures, Mayfield, Seven Seven Six, SOSV, Tenacity Venture Capital, John Parker, Kyle Vogt, fresh.fund.
# Multus: Revolutionizing Cell Culture Media for the Bioeconomy
Multus is a biotechnology company that designs animal-free, cost-effective cell culture media using AI-powered optimization to accelerate biomanufacturing across multiple industries, with an initial focus on cultivated meat.[1][2] Founded by three Imperial College London scientists, the company addresses a critical bottleneck in cellular agriculture: the reliance on expensive, ethically problematic animal serum-based growth media that has remained largely unchanged for over 60 years.[2]
The company's mission centers on making biomanufactured products—from cultivated meat to therapeutic proteins—accessible at global scale by fundamentally reimagining the media that enables cell growth.[2] Multus serves cultivated meat producers, biotech manufacturers, and other cellular agriculture companies seeking to reduce production costs, improve supply chain security, and eliminate animal-derived inputs. By developing proprietary formulations and production systems, Multus is removing a major economic and ethical barrier to scaling sustainable protein production and advanced biotherapies.
Multus was founded in 2019 (incorporated in 2020) by Cai Linton, Reka Tron, and Kevin Pan, three science and engineering students from Imperial College London who shared a passion for synthetic biology and sustainable food systems.[1][2] The founders recognized a fundamental contradiction: cultivated meat, positioned as an ethical and sustainable alternative to conventional animal agriculture, still relied on animal serum-based growth media—defeating the purpose of the innovation.[1]
The company achieved rapid early traction. By 2021, Multus had closed a £1.6 million funding round, grown its team from 6 to 11 scientists and engineers, joined the EIT Food Accelerator Network, and shipped its first product, Proliferum M, to over 10 companies.[1] The company continued scaling: in 2023, it raised £7.9 million and opened what it claimed was the world's first commercial-scale production plant for serum-free growth media.[3] In December 2024, Multus launched Proliferum B, an animal component-free alternative to fetal bovine serum (FBS) developed using its machine learning-driven system.[3]
Multus operates at the intersection of three converging trends: the cultivated meat industry's race to commercial viability, the broader bioeconomy's need for cost-effective biomanufacturing infrastructure, and the application of AI to biological design problems.[2]
The timing is critical. Cultivated meat companies face a "valley of death" where production costs remain too high for price-competitive retail products. Media costs represent a substantial portion of total production expenses, making Multus's cost-reduction focus directly aligned with industry needs.[3] More broadly, the company's platform addresses a systemic inefficiency: most cell culture media formulations date back over 60 years, representing untapped optimization potential across pharmaceuticals, food, materials, and other biomanufactured products.[2]
Multus influences the ecosystem by removing a critical technical and economic barrier to scaling cellular agriculture. By making serum-free media affordable and reliable, the company enables downstream cultivated meat producers to focus on their own innovations rather than solving media problems. This creates a multiplier effect across the industry—similar to how cloud infrastructure enabled software startups to scale without building data centers.
Multus is positioned as essential infrastructure for the bioeconomy's next phase of growth. The company's success depends on three factors: (1) achieving true cost parity or advantage over animal serum-based media at scale, (2) expanding beyond cultivated meat into adjacent biotech and pharmaceutical applications where cell culture media is equally critical, and (3) maintaining technological leadership as competitors inevitably enter the space.
The company's trajectory suggests ambitions beyond cultivated meat. Its framing as a platform for "the global bioeconomy" and emphasis on "life-extending medicines" and "climate-resilient foods" indicate plans to serve pharmaceutical, synthetic biology, and industrial biotech customers—markets substantially larger than cultivated meat alone.[2] As regulatory approval for cultivated meat accelerates globally and production scales, Multus's media will become increasingly central to the industry's economics. The question is whether the company can maintain its technical moat and cost advantage as the market matures and larger biotech firms develop competing solutions.
Multus has raised $12.3M across 3 funding rounds. Most recently, it raised $10.0M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $10.0M Series A | Astanor Ventures, Autism Impact Fund, Big Idea Ventures, LombardStreet Ventures, Mandi Ventures, Mayfield, Seven Seven Six, SOSV, Tenacity Venture Capital, John Parker, Kyle Vogt | |
| Jul 1, 2021 | $2.0M Seed | Autism Impact Fund, fresh.fund, Hanaco Ventures, Mayfield, Prime Ventures, SOSV, Amiad Solomon, John Parker | |
| May 1, 2020 | $250K Seed | Autism Impact Fund, Mayfield, SOSV, John Parker |